Advertisement

Organisation › Details
CureVac N.V. (Nasdaq: CVAC)
![]() |
Start | 2020-08-10 existent |
Predecessor | CureVac AG | |
![]() |
Industry | mRNA technology |
Industry 2 | mRNA-based drug | |
![]() |
Person | Haas, Franz-Werner (CureVac 202008– CEO joined 201206 as COO before Sygnis + Lion BIoscience) |
Person 2 | Hoerr, Ingmar (CureVac 201806– Chairman of Supervisory Board before 2000–201806 CEO + Co-Founder) | |
![]() |
Region | Netherlands_oo |
Country | Netherlands | |
City | n. a. | |
Address record changed: 2020-08-12 | ||
Basic data | Employees | n. a. |
Record changed: 2021-02-20 |
Advertisement

More documents for CureVac N.V. (Nasdaq: CVAC)
- [1] CureVac N.V.. (2/12/21). "Press Release: CureVac Initiates Rolling Submission with European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV". Tübingen & Boston, MA....
- [2] GlaxoSmithKline plc. (2/3/21). "Press Release: GSK and CureVac to Develop Next Generation mRNA COVID-19 Vaccines". London, Tübingen & Boston, MA....
- [3] CureVac N.V.. (1/28/21). "Press Release: CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares". Tübingen & Boston, MA....
- [4] CureVac N.V.. (1/25/21). "Press Release: CureVac Announces Proposed Public Offering of Common Shares". Tübingen & Boston, MA....
- [5] CureVac N.V.. (1/7/21). "Press Release: CureVac and Bayer Join Forces on COVID-19 Vaccine Candidate CVnCoV". Berlin, Tübingen & Boston; MA....
- [6] CureVac N.V.. (12/23/20). Web Site: Leadership – Executive Board, Supervisory Board and Scientific Advisory Board. [https://www.curevac.com, 12/23/20]...
- [7] CureVac N.V.. (12/9/20). "Press Release: CureVac and Fareva Sign Agreement for Fill & Finish Manufacturing of Curevac’s COVID-19 Vaccine Candidate, CVnCoV". Tübingen & Boston, MA....
- [8] CureVac N.V.. (12/4/20). "Press Release: CureVac Appoints Antony Blanc as Chief Business Officer and Chief Commercial Officer". Tübingen & Boston, MA....
- [9] Kaleido Biosciences, Inc.. (10/1/20). "Press Release: Kaleido Biosciences Appoints Daniel Menichella as President and Chief Executive Officer". Lexington, MA....
- [10] CureVac N.V.. (9/29/20). "Press Release: CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate. Study Conducted in Peru and Panama". Tübingen & Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top